News & Events

Game changing national summit for children with neurodevelopment disorders

06 June 2019
Events

Events

‘Approximately one in ten children in Australia meet criteria for a neurodevelopmental disorder’ Professor Adam Guastella, Michael Crouch Chair in Child and Youth Mental Health, clinical psychologist and clinical trials specialist based at Westmead Children’s Hospital and the Brain and Mind Centre, University of Sydney is leading a national effort where leading experts from universities and he...

GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex

03 June 2019
Medicinal Cannabis

- Achieved primary efficacy measure with both EPIDIOLEX doses as compared to placebo - - Represents the fifth consecutive positive Phase 3 pivotal trial for EPIDIOLEX - - Expect to file sNDA in Q4 2019 - Carlsbad, CA, May 6, 2019: GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the scien...

Medicinal Cannabis: Positive results in treatment of children with seizures from Tuberous Sclerosis Complex (TSC)

03 June 2019
Medicinal Cannabis

Medicinal Cannabis

Medicinal Cannabis: Positive results in treatment of children with seizures from Tuberous Sclerosis Complex (TSC) A phase 3 clinical trial has shown that the cannabis-based medicine Epidiolex ® (cannabidiol oral solution or CBD) manufactured and supplied by GW pharmaceuticals was successful in the treatment of seizures associated with Tuberous Sclerosis Complex (TSC). TSC is a rare genetic...

Cannabis-based medicine eases seizures in Dravet syndrome

15 January 2019
Medicinal Cannabis

Medicinal cannabis

A phase III clinical trial has shown the cannabis-based medicine Epidiolex® (cannabidiol oral solution) to reduce seizures in children with Dravet syndrome, a rare and severe form of childhood-onset epilepsy. Sydney Children’s Hospital, Randwick, was one of two sites in Australia to take part in the international study, which reinforced the safety and efficacy of the drug in reducing sei...

Medicinal Cannabis: safe for children with severe epilepsy

14 August 2018
Medicinal Cannabis

Medicinal Cannabis

Findings into the safety of Epidiolex®, an experimental cannabis-based treatment for severe drug-resistant epilepsy in children, have been published in the Medical Journal of Australia. Under the NSW Government funded Compassionate Access Scheme, children with the most severe forms of childhood epilepsy, who are too sick to participate in a clinical trial, have an opportunity to access a canna...

Researchers in Focus: Dr Tejaswi Kandula

21 June 2018
Researcher Profile

Researcher Profile

Dr Tejaswi Kandula is paediatric neurologist at Sydney Children’s Hospital, Randwick, with a special interest in researching peripheral neuropathy in childhood cancer survivors. Dr Kandula recently published her fourth paper on the subject in the American Medical Association’s top-ranking neurology journal, JAMA Neurology, which generated worldwide interest and has been viewed more than 4000 t...

Tackling muscular dystrophy every step of the way

20 June 2018
Research

Research

Dr Monkol Lek is a leading researcher in muscular dystrophy, a rare genetic disease affecting nerves and muscles around the body. Dr Lek is all too familiar with the disease, having suffered from muscle weakness in his legs while at university, which led, over ten years later, to a diagnosis of limb girdle muscular dystrophy. After leaving his job as a computer engineer and retraining as...

Introducing Kids Neuroscience Centre

20 June 2018

Big news! The Institute of Neuroscience and Muscle Research (INMR) has a new name: Kids Neuroscience Centre. The new brand identity reflects the joint mission of Kids Research and the Centre to drive excellence in paediatric health. While the name has changed, the vision to improve the lives of children affected by muscle, nerve and brain disease t...

New treatment reduces seizures in children with tuberous sclerosis complex

01 June 2018
Clinical trials

Clinical trials

Findings of a phase 3 clinical trial for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children have been published today in The Lancet Child & Adolescent Health. The international study was conducted in 25 countries, with centres across Australia led by Dr John Lawson, paediatric neurologist at Sydney Children's Hospital, Randwick and national leader in epi...

Neuroimmunology research bringing us closer to a cure: World MS Day 2018

30 May 2018
Multiple Sclerosis

Neuroimmunology

Associate Professor Fabienne Brilot-Turville is a cellular immunologist at Kids Neuroscience Centre, Kids Research, where she leads the Brain Autoimmunity Group in their search to understand the role that autoantibodies play in various neurological diseases. One class of neurological conditions that interest the Brain Autoimmunity Group is demyelinating disorders. Demyelinating disorders...

News & Events

Addresses

General Enquires

Links

Partners

Address

General Enquires

Links

Partners